TY - JOUR
T1 - 3D printed microfluidic devices for circulating tumor cells (CTCs) isolation
AU - Chen, Juhong
AU - Liu, Chun Yen
AU - Wang, Xinchang
AU - Sweet, Eric
AU - Liu, Nathaniel
AU - Gong, Xiaohua
AU - Lin, Liwei
N1 - Funding Information:
We thank the Hangzhou Wahaha Group Co. Ltd. (China) for supporting this research financially. Additional thanks go to Professor Lydia Sohn in the Dept. of Mechanical Engineering at the University of California, Berkeley for providing human breast cancer cell line (MCF-7/GFP).
Publisher Copyright:
© 2019 Elsevier B.V.
PY - 2020/2/15
Y1 - 2020/2/15
N2 - Isolation of circulating tumor cells (CTCs) from blood samples has important prognostic and therapeutic implications for cancer treatments, but the process is very challenging due to the low concentration of CTCs. In this study, we report a novel 3D printed microfluidic device functionalized with anti-EpCAM (epithelial cell adhesion molecule) antibodies to isolate CTCs from human blood samples. A 3D printing technology was utilized with specially designed interior structures to fabricate a microfluidic device with high surface area and fluid flow manipulation, increasing capture efficiency of tumor cells. These devices with the optimal flow rate (1 mL/h) and channel length (2 cm) were demonstrated to test three kinds of EpCAM positive cancer cell lines (MCF-7 breast cancer, SW480 colon cancer, and PC3 prostate cancer), and one kind of EpCAM negative cancer cell line (293T kidney cancer). Experimentally, the capture efficiency higher than 90% has been achieved, and the isolation of MCF-7 tumor cells from spiked human blood samples has also been demonstrated. Combined with DNA-based detection (e.g. polymerase chain reaction or DNA sequencing), the detection and analysis of released DNAs from captured tumor cells could be another future direction for clinical diagnosis and cancer treatment.
AB - Isolation of circulating tumor cells (CTCs) from blood samples has important prognostic and therapeutic implications for cancer treatments, but the process is very challenging due to the low concentration of CTCs. In this study, we report a novel 3D printed microfluidic device functionalized with anti-EpCAM (epithelial cell adhesion molecule) antibodies to isolate CTCs from human blood samples. A 3D printing technology was utilized with specially designed interior structures to fabricate a microfluidic device with high surface area and fluid flow manipulation, increasing capture efficiency of tumor cells. These devices with the optimal flow rate (1 mL/h) and channel length (2 cm) were demonstrated to test three kinds of EpCAM positive cancer cell lines (MCF-7 breast cancer, SW480 colon cancer, and PC3 prostate cancer), and one kind of EpCAM negative cancer cell line (293T kidney cancer). Experimentally, the capture efficiency higher than 90% has been achieved, and the isolation of MCF-7 tumor cells from spiked human blood samples has also been demonstrated. Combined with DNA-based detection (e.g. polymerase chain reaction or DNA sequencing), the detection and analysis of released DNAs from captured tumor cells could be another future direction for clinical diagnosis and cancer treatment.
UR - http://www.scopus.com/inward/record.url?scp=85077380612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077380612&partnerID=8YFLogxK
U2 - 10.1016/j.bios.2019.111900
DO - 10.1016/j.bios.2019.111900
M3 - Article
C2 - 31767348
AN - SCOPUS:85077380612
SN - 0956-5663
VL - 150
JO - Biosensors and Bioelectronics
JF - Biosensors and Bioelectronics
M1 - 111900
ER -